^
Association details:
| Biomarker: | MYC mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EXPLORING DIFFERENTIAL MUTATIONAL DISTRIBUTION BY TARGETED SEQUENCING IN A R-CHOP TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
Published date:
06/09/2023
Excerpt:
A cohort of 105 de novo DLBCL pts, uniformly treated with first-line R-CHOP, were studied...a subgroup of DHB pts characterized by mutations in MYC, PRDM1, or IRF4 (n = 15) had markedly inferior OS (5-year OS, log-rank, p = 0.0003, HR 3.34) compared to negative non-DHB pts (n = 55) or negative non-DHB/DHB pts (p = 0.0017, HR 2.7, n = 72).
DOI:
https://doi.org/10.1002/hon.3165_505
